Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT03562637
Registration number
NCT03562637
Ethics application status
Date submitted
6/06/2018
Date registered
19/06/2018
Date last updated
28/02/2024
Titles & IDs
Public title
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC
Query!
Scientific title
The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With High Risk, Early Stage Globo H-Positive Triple Negative Breast Cancer
Query!
Secondary ID [1]
0
0
OBI-822-011
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Triple Negative Breast Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Other interventions - adagloxad simolenin combined with OBI-821
Treatment: Devices - Globo H IHC Assay
Other interventions - Standard of care treatment
Experimental: Adagloxad simolenin + OBI-821 in conjunction with SOC - Participants will be administered adagloxad simolenin combined with OBI-821 for up to a total of 21 subcutaneous injections over a period of 100 weeks.
Patient will also receive standard of care (SOC) treatment.
Active Comparator: Standard of Care treatment - Study visit intervals will be identical to those in Arm 1.
Patient will receive standard of care (SOC) treatment.
Other interventions: adagloxad simolenin combined with OBI-821
In the neoadjuvant and adjuvant phases of the study for a total of 100 weeks; subcutaneously injections.
Treatment: Devices: Globo H IHC Assay
The Globo H IHC assay will be used to identify eligible patients who may clinically benefit from the OBI-822 treatment, defined by Globo H expression.
Other interventions: Standard of care treatment
Standard of care treatment consisting of observation alone, adjuvant capecitabine or platinum monotherapy over a 100 week period.
Query!
Intervention code [1]
0
0
Other interventions
Query!
Intervention code [2]
0
0
Treatment: Devices
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Measuring the effect of adagloxad simolenin (OBI-822)/OBI-821 treatment on improving invasive disease free survival (IDFS) in the study population.
Query!
Assessment method [1]
0
0
The outcome measure of the study is IDFS, defined by the STEEP system as the first occurrence of the time from the date of randomization to the date of first invasive disease recurrence (local, regional or distant), the date of secondary primary invasive cancer (breast or not), or the date of death from any cause.
Query!
Timepoint [1]
0
0
5 years
Query!
Secondary outcome [1]
0
0
Measuring the impact of adagloxad simolenin (OBI-822)/OBI-821 treatment in the study population on Overall Survival (OS).
Query!
Assessment method [1]
0
0
OS is defined as the time from randomization to date of death from any cause
Query!
Timepoint [1]
0
0
7 years
Query!
Secondary outcome [2]
0
0
Measuring the impact of adagloxad simolenin (OBI-822)/OBI-821 treatment in the study population on Quality of Life (QoL).
Query!
Assessment method [2]
0
0
QoL defined as time to definitive deterioration in Health-related Quality of Life (HRQOL) using the global health status/QoL scale from European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) and the European Quality of Life 5 Dimensions 5 Levels (EQ-5D-5L). QoL baseline established at randomization.
Definitive deterioration defined as a 5% worsening relative to baseline in the HRQOL scale score from EORTC QLQ-C30 questionnaires with no subsequent improvement above threshold, scored with the EORTC QLQ-C30 v3.0 Scoring Manual. The EQ-5D-5L questionnaire assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, rated by the patient. It is a standardized measure of health status to provide a simple, generic measure of health for clinical and economic appraisal. 28 questions have a 4 point scale: not at all(1) to very much(4). 2 questions have a 7-point scale: very poor (1) to excellent(7).
Query!
Timepoint [2]
0
0
7 years
Query!
Secondary outcome [3]
0
0
Measuring the impact of adagloxad simolenin (OBI-822)/OBI-821 treatment in the study population on Breast cancer-free interval (BCFI).
Query!
Assessment method [3]
0
0
BCFI is defined by the STEEP system as the first occurrence of the time from the date of randomization to the date of the first invasive disease recurrence (local, regional or distant), the date of ductal carcinoma in situ (ipsilateral or contralateral), or the date of death from breast cancer
Query!
Timepoint [3]
0
0
7 years
Query!
Secondary outcome [4]
0
0
Measuring the impact of adagloxad simolenin (OBI-822)/OBI-821 treatment in the study population on Distant disease-free survival (DDFS).
Query!
Assessment method [4]
0
0
DDFS is defined by the STEEP system as the first occurrence of the time from the date of randomization to the date of the first distant disease recurrence, the date of the second primary invasive cancer (non-breast), or the date of death from any cause
Query!
Timepoint [4]
0
0
7 years
Query!
Secondary outcome [5]
0
0
Incidence and severity of adverse events (AEs) [Time Frame: AEs will be noted as it occurs, with a timeframe from beginning of randomization to 4 weeks after last dose of study treatment.]
Query!
Assessment method [5]
0
0
Adverse Events will be graded and recorded by investigators per National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0).
Query!
Timepoint [5]
0
0
2 years
Query!
Eligibility
Key inclusion criteria
- Documented radiographic and histopathologic confirmed primary localized invasive
breast cancer.
- Histologically documented TNBC (estrogen receptor negative [ER-]/progesterone receptor
negative [PR-]/human epidermal growth factor 2 negative [HER2-]) defined as
ER-negative and PR-negative (=5% positive cells stain by IHC for both ER and PR), and
negative HER2/neu- status, confirmed on tumor sample.
- HER2/neu negative will be defined as one of the following criteria:
- IHC 0 or 1+
- Single-probe average HER2 gene copy number of <6 signals/nucleus
- Dual-probe fluorescent in-situ hybridization (FISH) HER2/neu chromosome 17
(CEP17) non-amplified ratio of <2
- Globo H IHC H-score =15 from the residual primary site/or lymph node (if primary site
is not available) tumor obtained at time of definitive surgery. Globo H expression
will be determined during pre-screening by Central lab. Instructions for submission of
slides/tumor tissue blocks are provided in the protocol and study Lab Manual.
- No evidence of metastatic disease in chest, abdomen and pelvis by CT or other adequate
imagining during the Screening Phase. Imaging within 3 months prior to randomization
is acceptable as baseline scan. Bone scans and imaging of the brain at screening is
optional, and should be symptom directed.
- High risk patients with no evidence of disease after completing standard treatment and
meeting ONE of the following criteria:
- Neoadjuvant chemotherapy followed by definitive surgery: Residual invasive
disease following neoadjuvant chemotherapy defined as: A contiguous focus of
residual invasive cancer in the surgical breast measuring =1 cm in diameter
and/or with residual invasive cancer in at least one axillary node
(micrometastases or macrometastases), as determined by local pathology review.
- Definitive surgery followed by adjuvant chemotherapy: Pathological Stage IIB,
Stage IIIA , Stage IIIB, or Stage IIIC disease according to the 8th edition of
the American Joint Committee on Cancer (AJCC) Cancer Staging Manual.
- Must have completed a standard taxane, and/or anthracycline-based multi-agent
chemotherapy regimen either in the neoadjuvant or adjuvant setting (e.g., National
Comprehensive Cancer Network recommended regimens):.
- At least 4 cycles of a standard multi-agent chemotherapy regimen must have been
received, unless precluded by toxicities
- Post operative adjuvant capecitabine or a platinum monotherapy in patients with
residual disease after neoadjuvant chemotherapy is allowed.
- Randomization must occur within 12 weeks after completion of standard of care
treatment (surgery and/or chemotherapy) and within 46 weeks from the date of
definitive surgery. Note: patients receiving adjuvant capecitabine or platinum
monotherapy after neoadjuvant multi-agent chemotherapy may be randomized and initiate
study treatment during (or within 12 weeks after completion of) the adjuvant
capecitabine or platinum monotherapy.
- All treatment-related toxicities resolved to Grade <1 on National cancer institute
Common Terminology Criteria for Adverse Events (NCI-CTCAE version 5.0) criteria
(except hair loss and =Grade 2 neuropathy, which are acceptable).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Females must be either of non-childbearing potential, i.e., surgically sterilized
(have documented sterilization, bilateral oophorectomy/salpingectomy at least 3 months
before the start of the trial and/or hysterectomy), or one year postmenopausal; or if
of childbearing potential must have a negative pregnancy test (urine or serum) at
randomization.
- Males and females of childbearing potential and their partners must be willing to use
effective contraception during the entire Treatment Phase period and for at least 4
weeks (28 days) after the last dose of study treatment.
- Adequate hematological, hepatic and renal function as defined below:
- Absolute neutrophil count (ANC) =1,500/µL
- Platelets =75,000/µL
- Hemoglobin =8.5g/dL
- Serum creatinine =1.5 × upper limit of normal (ULN) or calculated creatinine
clearance =55 mL/min for subjects with creatinine levels >1.5 × institutional ULN
(glomerular filtration rate can also be used in place of creatinine or creatinine
clearance may be calculated per institutional standard)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =3 × ULN
- Alkaline Phosphatase (ALP) =2.5 × ULN
- Serum total bilirubin =1.5 × ULN (unless Gilbert's disease is documented)
- Consent to participate with a signed and dated Institutional Review Board
(IRB)/Independent Ethics Committee (IEC) approved patient informed consent for the
study prior to beginning any specific study procedures.
- Ability to understand and willingness to complete all protocol required procedures.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Local recurrence of or previous history of ipsilateral or contralateral invasive
breast cancer within 10 years prior to randomization.
- Definitive clinical or radiologic evidence of metastatic disease
- Synchronous bilateral breast cancer, unless both tumors are confirmed as TNBC.
- Have received any post-operative immunotherapy with antigen, antibody, immune
checkpoint inhibitors (Programmed cell death-1 [PD-1]/ Programmed cell
death-ligand-1inhibitors [PD-L-1], anti-cytotoxic T lymphocyte associated protein 4
[CTLA 4] therapy), or other anti-cancer vaccines (neoadjuvant receipt of immune
checkpoint inhibitors will not be exclusionary if the patient meets all other
eligibility criteria).
- Concomitant treatment with approved anticancer therapy or immunotherapy including
checkpoint inhibitors (e.g. PD-1 inhibitors) or other investigational therapy, if
expected during the study. Adjuvant capecitabine or platinum monotherapy is allowed
during the study.
- A history of other malignancies (except non melanoma skin carcinoma, carcinoma in situ
of the uterine cervix, follicular or papillary thyroid cancer) within 5 years prior to
randomization.
- Have any active autoimmune disease or disorder that requires systemic
immunosuppressive/immunomodulatory therapy. NOTE: Autoimmune diseases that are
confined to the skin (e.g., psoriasis) that can be treated with topical steroids alone
are allowed during the study.
- Oral/parenteral corticosteroid treatment (>5 mg/day of prednisone/equivalent), within
2 weeks prior to randomization or anytime during the study. NOTE: inhaled steroids for
treatment of asthma; and topical steroids are allowed during the study.
- Any known uncontrolled concurrent illness that would limit compliance with study
requirements, including but not limited to ongoing or active infections, symptomatic
congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric
disorders, or substance abuse.
- Any known hypersensitivity to active/inactive ingredients in the study drug
formulation or known severe allergy or anaphylaxis to fusion proteins.
- Prior receipt of a glycoconjugate vaccine for cancer immunotherapy.
- Known history or positive for human immunodeficiency virus (HIV positive), unless on
effective anti-retroviral therapy with undetectable viral load within 6 months of
therapy (note: HIV testing not required for study entry).
- Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to
randomization. Patients who have completed curative therapy for HCV are eligible. For
patients with evidence of chronic HBV infection, the HBV viral load must be
undetectable on suppressive therapy. (note: HBV/HCV testing is not required for study
entry).
- Any condition, including significant diseases and/or laboratory abnormalities that
would place the patient at unacceptable risk for study participation.
- Currently pregnant or breastfeeding women.
- Currently participating in or has participated in a breast cancer therapeutic clinical
trial within 4 weeks (24 days) prior to randomization.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
5/12/2018
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
30/12/2027
Query!
Actual
Query!
Sample size
Target
668
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Query!
Recruitment hospital [1]
0
0
Westmead Hospital - Westmead
Query!
Recruitment hospital [2]
0
0
Cancer Care Service, Hervey Bay Hospital - Urraween
Query!
Recruitment hospital [3]
0
0
Slade Pharmacy - East Melbourne
Query!
Recruitment hospital [4]
0
0
Cabrini Malvern - Malvern
Query!
Recruitment hospital [5]
0
0
Breast Cancer Research Centre - Nedlands
Query!
Recruitment hospital [6]
0
0
St Vincent's Hospital Sydney - Darlinghurst
Query!
Recruitment hospital [7]
0
0
Gosford Hospital - Gosford
Query!
Recruitment hospital [8]
0
0
St John of God Murdoch Hospital - Murdoch
Query!
Recruitment hospital [9]
0
0
Eastern Health - Maroondah Hospital - Ringwood East
Query!
Recruitment postcode(s) [1]
0
0
2145 - Westmead
Query!
Recruitment postcode(s) [2]
0
0
4655 - Urraween
Query!
Recruitment postcode(s) [3]
0
0
3002 - East Melbourne
Query!
Recruitment postcode(s) [4]
0
0
3144 - Malvern
Query!
Recruitment postcode(s) [5]
0
0
- Nedlands
Query!
Recruitment postcode(s) [6]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [7]
0
0
2250 - Gosford
Query!
Recruitment postcode(s) [8]
0
0
6150 - Murdoch
Query!
Recruitment postcode(s) [9]
0
0
3135 - Ringwood East
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Florida
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Illinois
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Maryland
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Michigan
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Mississippi
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
New Jersey
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Texas
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Washington
Query!
Country [10]
0
0
Brazil
Query!
State/province [10]
0
0
Bahia
Query!
Country [11]
0
0
Brazil
Query!
State/province [11]
0
0
Ceara
Query!
Country [12]
0
0
Brazil
Query!
State/province [12]
0
0
Espirito Santo
Query!
Country [13]
0
0
Brazil
Query!
State/province [13]
0
0
Minas Gerais
Query!
Country [14]
0
0
Brazil
Query!
State/province [14]
0
0
Parana
Query!
Country [15]
0
0
Brazil
Query!
State/province [15]
0
0
Para
Query!
Country [16]
0
0
Brazil
Query!
State/province [16]
0
0
Pernambuco
Query!
Country [17]
0
0
Brazil
Query!
State/province [17]
0
0
Piaui
Query!
Country [18]
0
0
Brazil
Query!
State/province [18]
0
0
Rio Grande Do Sul
Query!
Country [19]
0
0
Brazil
Query!
State/province [19]
0
0
Rondona
Query!
Country [20]
0
0
Brazil
Query!
State/province [20]
0
0
Roraima
Query!
Country [21]
0
0
Brazil
Query!
State/province [21]
0
0
Santa Catarina
Query!
Country [22]
0
0
Brazil
Query!
State/province [22]
0
0
Sao Paulo
Query!
Country [23]
0
0
China
Query!
State/province [23]
0
0
Beijing
Query!
Country [24]
0
0
China
Query!
State/province [24]
0
0
Guangdong
Query!
Country [25]
0
0
China
Query!
State/province [25]
0
0
Guangxi
Query!
Country [26]
0
0
China
Query!
State/province [26]
0
0
Heilongjiang
Query!
Country [27]
0
0
China
Query!
State/province [27]
0
0
Hubei
Query!
Country [28]
0
0
China
Query!
State/province [28]
0
0
Hunan
Query!
Country [29]
0
0
China
Query!
State/province [29]
0
0
Jiangsu
Query!
Country [30]
0
0
China
Query!
State/province [30]
0
0
Jilin
Query!
Country [31]
0
0
China
Query!
State/province [31]
0
0
Liaoning
Query!
Country [32]
0
0
China
Query!
State/province [32]
0
0
Sichuan
Query!
Country [33]
0
0
China
Query!
State/province [33]
0
0
Tianjin
Query!
Country [34]
0
0
China
Query!
State/province [34]
0
0
Zhejiang
Query!
Country [35]
0
0
Hong Kong
Query!
State/province [35]
0
0
Hong Kong
Query!
Country [36]
0
0
Korea, Republic of
Query!
State/province [36]
0
0
Busan
Query!
Country [37]
0
0
Korea, Republic of
Query!
State/province [37]
0
0
Goyang-si
Query!
Country [38]
0
0
Korea, Republic of
Query!
State/province [38]
0
0
Incheon
Query!
Country [39]
0
0
Korea, Republic of
Query!
State/province [39]
0
0
Seongnam-si
Query!
Country [40]
0
0
Korea, Republic of
Query!
State/province [40]
0
0
Seoul
Query!
Country [41]
0
0
Korea, Republic of
Query!
State/province [41]
0
0
Suwon-si
Query!
Country [42]
0
0
Mexico
Query!
State/province [42]
0
0
Coahuila
Query!
Country [43]
0
0
Mexico
Query!
State/province [43]
0
0
Del Tialpan
Query!
Country [44]
0
0
Mexico
Query!
State/province [44]
0
0
Nuevo Leon
Query!
Country [45]
0
0
Mexico
Query!
State/province [45]
0
0
Chihuahua
Query!
Country [46]
0
0
Peru
Query!
State/province [46]
0
0
Surquillo
Query!
Country [47]
0
0
Peru
Query!
State/province [47]
0
0
Arequipa
Query!
Country [48]
0
0
Peru
Query!
State/province [48]
0
0
Lima
Query!
Country [49]
0
0
Poland
Query!
State/province [49]
0
0
Gdansk
Query!
Country [50]
0
0
Poland
Query!
State/province [50]
0
0
Kraków
Query!
Country [51]
0
0
Poland
Query!
State/province [51]
0
0
Warsaw
Query!
Country [52]
0
0
Poland
Query!
State/province [52]
0
0
Lódz
Query!
Country [53]
0
0
Russian Federation
Query!
State/province [53]
0
0
Republic Of Mordovia
Query!
Country [54]
0
0
Russian Federation
Query!
State/province [54]
0
0
Arkhangelsk
Query!
Country [55]
0
0
Russian Federation
Query!
State/province [55]
0
0
Chelyabinsk
Query!
Country [56]
0
0
Russian Federation
Query!
State/province [56]
0
0
Krasnoyarsk
Query!
Country [57]
0
0
Russian Federation
Query!
State/province [57]
0
0
Moscow
Query!
Country [58]
0
0
Russian Federation
Query!
State/province [58]
0
0
Nizhny Novgorod
Query!
Country [59]
0
0
Russian Federation
Query!
State/province [59]
0
0
Omsk
Query!
Country [60]
0
0
Russian Federation
Query!
State/province [60]
0
0
Orenburg
Query!
Country [61]
0
0
Russian Federation
Query!
State/province [61]
0
0
Pesochnyy
Query!
Country [62]
0
0
Russian Federation
Query!
State/province [62]
0
0
Saint Petersburg
Query!
Country [63]
0
0
Russian Federation
Query!
State/province [63]
0
0
Saint-Petersburg
Query!
Country [64]
0
0
Russian Federation
Query!
State/province [64]
0
0
St. Petersburg
Query!
Country [65]
0
0
Russian Federation
Query!
State/province [65]
0
0
Tomsk
Query!
Country [66]
0
0
Russian Federation
Query!
State/province [66]
0
0
Volzhskiy
Query!
Country [67]
0
0
Russian Federation
Query!
State/province [67]
0
0
Yaroslavl
Query!
Country [68]
0
0
South Africa
Query!
State/province [68]
0
0
Gauteng
Query!
Country [69]
0
0
Taiwan
Query!
State/province [69]
0
0
Changhua
Query!
Country [70]
0
0
Taiwan
Query!
State/province [70]
0
0
Kaohsiung
Query!
Country [71]
0
0
Taiwan
Query!
State/province [71]
0
0
Taichung
Query!
Country [72]
0
0
Taiwan
Query!
State/province [72]
0
0
Tainan
Query!
Country [73]
0
0
Taiwan
Query!
State/province [73]
0
0
Taipei
Query!
Country [74]
0
0
Ukraine
Query!
State/province [74]
0
0
Dnipro
Query!
Country [75]
0
0
Ukraine
Query!
State/province [75]
0
0
Ivano-Frankivsk
Query!
Country [76]
0
0
Ukraine
Query!
State/province [76]
0
0
Kharkiv
Query!
Country [77]
0
0
Ukraine
Query!
State/province [77]
0
0
Kherson
Query!
Country [78]
0
0
Ukraine
Query!
State/province [78]
0
0
Kryvyi Rih
Query!
Country [79]
0
0
Ukraine
Query!
State/province [79]
0
0
Kyiv
Query!
Country [80]
0
0
Ukraine
Query!
State/province [80]
0
0
Lutsk
Query!
Country [81]
0
0
Ukraine
Query!
State/province [81]
0
0
Odesa
Query!
Country [82]
0
0
Ukraine
Query!
State/province [82]
0
0
Zaporizhzhia
Query!
Country [83]
0
0
Ukraine
Query!
State/province [83]
0
0
Zhytomyr
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
OBI Pharma, Inc
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The GLORIA study is a Phase III, randomized, open-label study to prospectively evaluate the
efficacy and safety of adagloxad simolenin (OBI 822)/OBI-821 in the adjuvant treatment of
patients with high risk, early stage Globo-H Positive TNBC.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT03562637
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Hope Rugo, MD
Query!
Address
0
0
University of California, San Francisco
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
OBI Pharma CT.gov Assistant
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
1-619-537-7821
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT03562637
Download to PDF